CliffBio
biologic

Benefix

Coagulation Factor IX (Recombinant)

Loss of exclusivityFebruary 2009projected — 12-year biologic exclusivity estimate
CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand nameBenefix
Active ingredientCoagulation Factor IX (Recombinant)
Strength250IU/ML
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 1997
Marketing statusRx

More from Wyeth

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Benefix patent cliff — loss of exclusivity February 2009 | CliffBio